Evidence map›Paper›PMID 28076329›Full record

Trial reportOncotarget2017

Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09).

Dok Hyun Yoon, Byeong Seok Sohn, Sung Yong Oh, Won-Sik Lee, Sang Min Lee, Deok-Hwan Yang, Jooryung Huh, Cheolwon Suh

Open access · diamondAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Dok Hyun YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Byeong Seok SohnDepartment of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.
Sung Yong OhDepartment of Internal Medicine, Dong-A University Hospital, Busan, Korea.
Won-Sik LeeDepartment of Hemato-Oncology, Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
Sang Min LeeDepartment of Hemato-Oncology, Internal Medicine, Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.
Deok-Hwan YangDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Hwasun, Korea.
Jooryung HuhDepartment of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Cheolwon SuhDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Inje University Busan Paik Hospital · KRUlsan College · KRAsan Medical Center · KRDong-A University Hospital · KRInje University Sanggye Paik Hospital · KRUniversity of Ulsan · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe appropriate number of chemotherapy cycles for limited stage diffuse large B-cell lymphoma (DLBCL) patients without gross residual lesions after complete resection, has not been specifically questioned. We performed a multicenter, single-arm, phase 2 study to investigate the feasibility of 3 cycles of abbreviated R-CHOP chemotherapy in low-risk patients with completely resected localized CD20+ DLBCL.

resultsBetween December 2010 and May 2013, we recruited 23 patients. One was excluded due to ineligibility, and hence, 22 were included in the final analysis. The primary sites comprised the intestine (n = 15), cervical lymph nodes (n = 4), stomach (n = 1), tonsil (n = 1), and spleen (n = 1). All patients successfully completed the 3 cycles of planned R-CHOP chemotherapy. Over a median follow-up of 39.5 months (95% confidence interval, 29.9-47.1 months), both the estimated 2-year disease-free survival and overall survival rates was 95% confidence interval, 85.9-104.1%. Only one patient with an international prognostic index of 2 experienced relapse and died. The most common grade 3 or 4 toxicity condition included neutropenia (n = 8, 36.4%). Three patients experienced grade 3 febrile neutropenia, but no grade 3 or 4 non-hematologic toxicity was observed. MATERIALS AND

methodsDLBCL patients without residual lesions after resection were enrolled and R-CHOP chemotherapy was repeated at 3-week-intervals over 3 cycles. The primary endpoint was 2-year disease-free survival.

conclusionsThree cycles of abbreviated R-CHOP immunochemotherapy is feasible for completely resected low risk localized DLBCL.

Indexed as

AdultAgedAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDisease-Free SurvivalDoxorubicinFemaleHumansImmunotherapyKaplan-Meier EstimateLymphoma, Large B-Cell, DiffuseMaleMiddle AgedPrednisoneAntibodies, Monoclonal, Murine-DerivedAntigens, CD20CyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineabbreviated cycles and R-CHOP chemotherapycomplete resectiondiffuse large B-cell lymphomalimited stage

Identifiers

PMID28076329
PMCPMC5355104
OpenAlexW2568592844

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.